Financials

Discussions Technicals Seasonals

SPERM fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Spermosens AB engages in the research and development of medical device for diagnosing male infertility. It develops a chip that employs sperm-specific receptor proteins of oocyte-origin that binds and induces a biochemical response. The response is then analyzed and determines the viability of the sperm. The company was founded by Kushagr Punyanis and Sudha Srivastavas on October 18, 2018 and is headquartered in Lund, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

SPERM does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company